Bavarian Nordic reaches required RSV cases in phase III trial of vaccine
![Photo: Sven Hoppe/AP/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/15570985/c0hhcn/ALTERNATES/schema-16_9/22144625829343-6723x4233ma.jpg)
In just one virus season, Bavarian Nordic has accrued enough cases of respiratory syncytial virus in its enrolled patient population of people in the over-60s to move a phase III of a vaccine to the next step, the Danish vaccine maker reported in a press release Tuesday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.